On June 14, 2001 Asensio & Company, Inc. (“Asensio”) delivered a (9) nine-page letter to the Research Frontiers Inc.’s (NASDAQ: REFR) (Price: $14.15) Board of Directors. The letter concerned the public record REFR has created […]
November 15, 2001 Board of Directors Research Frontiers Incorporated 240 Crossways Park Drive Woodbury, NY 11797-2033 Attention: Victor F. Keen, Secretary Re: Information request concerning certain questionable Research Frontiers Inc. (“REFR”) transactions. Notification of Asensio […]
VIA FACSIMILE # (516) 364-3798 June 14, 2001 Board of Directors Research Frontiers Incorporated 240 Crossways Park Drive Woodbury, NY 11797-2033 Attention: Robert L. Saxe Dear Directors: Asensio & Company, Inc. ("Asensio") is a member […]
Today, Asensio & Company, Inc. issued three equity research reports regarding Hemispherx Biopharma, Inc.’s (AMEX Symbol: HEB) (Price: $4.99) recent large questionable stock sales and the flurry of releases that followed days later. The reports […]
On November 5, 2001 Hemispherx Biopharma, Inc. (AMEX: HEB) (Price: $4.99) announced it had extended the expiration date for its warrants to November 21, 2001, “due to difficulties being experienced by the global investment community.” […]
On December 4, 2001 Hemispherx Biopharma, Inc. (AMEX: HEB) (Price: $4.99) claimed that a new report issued by the U.S. Agency for Healthcare Research and Quality (“AHRQ”) on Chronic Fatigue Syndrome (“CFS”) confirmed Ampligen’s efficacy. […]
In response to inquiries about Hemispherx Biopharma, Inc’s (AMEX: HEB) (Price: $4.99) recent bio-terrorism and smallpox claims, Hemispherx issued a press release dated December 6, 2001 titled “United States Military Sponsored Research on Hemispherx Biopharma’s […]
Research Frontiers Inc. (NASDAQ: REFR) (Price: $16.30) is promoting the claim that SPD Inc. (“SPD”) “is now in the mass production phase.” SPD is a Korean company with no public record other than press releases […]
A Sinking Feeling – eCompany Now
The U.S. General Accounting Office released a report titled “Improvements Needed in the Amex Listing Program” on November 27th. The GAO’s investigation and the resulting report were ordered by Congressman John Dingell, based in part […]
Short seller questions firm’s drug statement – Philadelphia Business Journal
During the last nine months Research Frontiers Incorporated (NASDAQ: REFR) (Price: $17.46) used over $8 million in a futile attempt to prop-up its own stock. Last year REFR spent $3.3 million trading its own stock […]
November 28, 2001 (Amended on November 30, 2001) Research Frontiers Incorporated (NASDAQ: REFR) (Price: $17.30) has an ongoing agreement with Ailouros Ltd., which REFR described as a “London based institutional money management fund” that had […]
Asensio’s zest for battle really sets him apart. Brett Nelson, Forbes
Short Story – Forbes
On November 5, 2001 a release titled “TTF Aerospace Teams with InspecTech to Offer SPD Equipped Armored Cockpit Doors” was distributed to investors. The release supposedly concerned a potential use for Research Frontiers Incorporated’s (NASDAQ: […]
Yesterday Hemispherx announced it was launching an “experimental program to treat potential smallpox outbreaks….” On November 2, 2001 Hemispherx issued another release promoting Carter’s claims about the applicability of Hemispherx’s “technology to the current crises […]
Smallpox Treatment or Snake Oil? – Wired News
Polymedica Corporation (NASDAQ: PLMD)(Price: $16.61) and its officers are the subject of a Federal Bureau of Investigation (“FBI”) criminal investigation. In November 2000 PLMD’s accounting and Medicare compliance practices were questioned and the company’s stock […]
Thomas McGuire manages the SAFECO Growth Opportunities Fund (“Safeco”). Safeco is Polymedica Corporation’s (NASDAQ: PLMD)(Price: $17.40) largest single investor. In July Mr. McGuire was quoted in the New York Times and the Boston Globe saying […]
On August 14, 2001 American Stock Exchange (“AMEX”) listed Hemispherx Biopharma, Inc. (AMEX: HEB) (Price: $3.85) reported shares outstanding of 30,330,382 shares as of June 30, 2001. Hemispherx was exposed as a medical stock scam […]
In its most recent annual report Hemispherx Biopharma Inc. (AMEX: HEB) (Price: $4.35) claims that HEB is developing a European organization and infrastructure to have a basic marketing and distribution system in place pending approval […]
Interview With a Short Seller – The Motley Fool
Asensio has produced perhaps the best public record of stock calls in the business. Zeke Ashton & Whitney Tilson, TheMotleyFool.com
‘Short’ Sellers Sit This One Out as Market Reopens – Los Angeles Times
Asensio & Company, Inc. believes that Research Frontiers Incorporated’s (NASDAQ: REFR) (Price: $14.41) long running stock promotion typifies the class of questionable market activity that contributes to economic instability. To date, Asensio & Company has […]
Research Frontiers Incorporated (Nasdaq: REFR) (Price: $16) and its insiders have been able to profit from selling REFR stock to the public, despite its 35-year history of uninterrupted losses and unequivocal commercial failure, partly as […]
Bright Dreams of Dim Success – Newsday
A recently published Research Frontiers Incorporated (Nasdaq: REFR) (Price: $16.90) stock promotion story leads with its “solid patent” claim. REFR constantly promotes that it controls 365 SPD patents and patent applications throughout the world. Apparently, […]
INVESTOR PROFILE – Short seller Asensio unrepentant – Reuters
© Asensio.com. All rights reserved.